HOOKIPA Q1 net loss $19.7M; cash $110M; milestones from Roche and Gilead; Phase 2 data on track for Q2 2023

HOOKIPA Pharma Inc.

2023-Q1 EPS reported -$0.27 revenue$3,176,000

Q1 net loss $19.7M vs $18.0M YoY; revenue $3.2M (up from $1.4M) on higher collaboration recognition.
Cash $110.0M at March 31, 2023, down from $113.4M at Dec 31, 2022; used in operations partly offset by collaboration funds.
Achieved $10M milestone from Roche for HB-700 (KRAS-mutated cancers) and $5M from Gilead for HB-400 (chronic hepatitis B).
Phase 2 data for HB-200 in HPV16+ head and neck cancer with pembrolizumab expected in Q2 2023; Phase 1 trials initiated for HB-300 and HB-400.
Appointed Terry Coelho to Board of Directors; preclinical data presented at AACR on arenaviral combo with Roche's PD1-IL2v.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

HOOKIPA Pharma Inc. reported First Quarter 2023 results: revenue $3.2 million, net income $19.7 million.

Period: First Quarter 2023
Revenue: $3.2 million
Net income: $19.7 million
Result: reported results

Exact text from the filing

Revenue was $3.2 million for the three months ended March 31, 2023 compared to $1.4 million for the three months ended March 31, 2022.

View on SEC.gov

Browse all earnings releases →

HOOKIPA Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-009248

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.